Table 3.
Summary of oligodendrocyte conversion
| Species | Cell source |
Reprogramming factors | Target cell type (Efficiency) | Duration (Days) |
Self-renewal | In vitro disease modeling | In vivo transplantation | References |
|---|---|---|---|---|---|---|---|---|
| Mouse | Fibroblasts | SOX10, OLIG2, NKX6.2 | PLP1＋ iOPCs (>20%) | >21 days |
>passage 5 | Not shown | Newborn shiverer mice | Najm et al., 2013 |
| MBP＋ iOLs (Not shown) |
>24 days | |||||||
| Mouse | Fibroblasts | SOX10, OLIG2, ZFP536 | O4＋ iOPCs (>15%) | >21 days |
Not shown | Not shown | Newborn shiverer mice | Yang et al., 2013 |
| MBP＋ iOLs (>10%) |
>24 days | |||||||
| Mouse | Fibroblasts | OCT4 | A2B5＋ iOPCs (>90%) | >35 days |
>passage 31 | Not shown | Adult rat SCI models | Kim et al., 2015 |
| MBP＋ iOLs (Not shown) | >63 days | |||||||
| Mouse | Astrocytes | SOX10 | NG2＋ iOPCs (>80%) | >16 days | Not shown | Not shown | In vivo conversion in cuprizone-induced demyelinated mice | Khanghahi et al., 2018 |
| Mouse | Astrocytes | SOX2 | PDGFRα＋ iOPCs (>70%) | >14 days | Not shown | Not shown | In vivo conversion in cuprizone-induced demyelinated mice | Farhangi et al., 2019 |
| Mouse | Fibroblasts | Chemical condition (M9) | A2B5＋ iOPCs (>60%) |
>18 days |
>passage 8 | Not shown | Not shown | Chang Liu et al., 2019 |
| MBP＋ iOLs (Not shown) | >28 days | |||||||
| Human | Fibroblasts | OCT4 | A2B5＋ iOPCs (∼10%) | >14 days |
>passage 10 | Not shown | Adult shiverer mice and EAE-induced model | Yun et al., 2022 |
| MBP＋ iOLs (∼3%) | >50 days |